BRPI1009576A2 - anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente. - Google Patents

anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.

Info

Publication number: BRPI1009576A2
Authority: BR; Brazil
Prior art keywords: antibody; cloning; patient; treating; producing
Prior art date: 2009-03-11

Application number

BRPI1009576A

Other languages

English (en)

Inventor

Alastair David Griffiths Lawson

Bryan John Smith

Daniel John Lightwood

Kerry Louise Tyson

Neil Gozzard

Roger Thomas Palframan

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-11

Filing date

2010-03-10

Publication date

2016-03-08

2010-03-10 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2016-03-08 Publication of BRPI1009576A2 publication Critical patent/BRPI1009576A2/pt

2020-04-07 Publication of BRPI1009576B1 publication Critical patent/BRPI1009576B1/pt

2021-05-25 Publication of BRPI1009576B8 publication Critical patent/BRPI1009576B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dispersion Chemistry (AREA)
Otolaryngology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI1009576A 2009-03-11 2010-03-10 anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13. BRPI1009576B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0904214.4A GB0904214D0 (en)	2009-03-11	2009-03-11	Biological products
GB0904214.4		2009-03-11
PCT/GB2010/000432 WO2010103274A1 (en)	2009-03-11	2010-03-10	Antibody molecules having binding specificity for human il-13

Publications (3)

Publication Number	Publication Date
BRPI1009576A2 true BRPI1009576A2 (pt)	2016-03-08
BRPI1009576B1 BRPI1009576B1 (pt)	2020-04-07
BRPI1009576B8 BRPI1009576B8 (pt)	2021-05-25

Family

ID=40600884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009576A BRPI1009576B8 (pt)	2009-03-11	2010-03-10	anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13.

Country Status (27)

Country	Link
US (3)	US8691233B2 (pt)
EP (2)	EP3168235A1 (pt)
JP (2)	JP5836130B2 (pt)
KR (1)	KR101773505B1 (pt)
CN (1)	CN102388066B (pt)
AR (1)	AR075849A1 (pt)
AU (1)	AU2010222693B2 (pt)
BR (1)	BRPI1009576B8 (pt)
CA (1)	CA2754539C (pt)
CY (1)	CY1118640T1 (pt)
DK (1)	DK2406283T3 (pt)
EA (1)	EA032222B1 (pt)
ES (1)	ES2615978T3 (pt)
GB (1)	GB0904214D0 (pt)
HR (1)	HRP20170234T1 (pt)
HU (1)	HUE031923T2 (pt)
IL (1)	IL215014A (pt)
LT (1)	LT2406283T (pt)
ME (1)	ME02607B (pt)
MX (1)	MX2011009390A (pt)
PL (1)	PL2406283T3 (pt)
PT (1)	PT2406283T (pt)
RS (1)	RS55734B1 (pt)
SI (1)	SI2406283T1 (pt)
TW (1)	TWI476004B (pt)
UY (1)	UY32489A (pt)
WO (1)	WO2010103274A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0904214D0 (en) *	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
WO2016113217A1 (en) *	2015-01-12	2016-07-21	Medimmune Limited	Il-13 binding proteins and uses thereof
EP4276108A3 (en)	2016-04-27	2024-01-24	AbbVie Inc.	Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP3532500A1 (en) *	2016-10-31	2019-09-04	Vectura Limited	Inhalable powder composition comprising il-13 antibody
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN109776677B (zh) *	2017-11-15	2023-11-03	尚华科创投资管理（江苏）有限公司	一种人源化抗il-13抗体及其制备方法和应用
AU2019205489A1 (en) *	2018-01-05	2020-06-25	Amgen, Inc.	Anti-MCT1 antibodies and uses thereof
MA55204A (fr)	2019-03-06	2022-01-12	Regeneron Pharma	Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
SG11202109002XA (en)	2019-03-21	2021-09-29	Regeneron Pharma	Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
GB201919061D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
CN115335062A (zh) *	2020-01-10	2022-11-11	达因疗法公司	肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途
WO2021142217A1 (en) *	2020-01-10	2021-07-15	Dyne Thereapeutics, Inc.	Muscle targeting complexes and uses thereof for modulation of milck1
TW202216771A (zh)	2020-06-26	2022-05-01	德商拜耳廠股份有限公司	用於治療應用之ccr8抗體
CA3241374A1 (en)	2021-12-30	2023-07-06	Gregory GEBA	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
AR133647A1 (es)	2023-08-25	2025-10-22	Proteologix Us Inc	Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
CA1340288C (en)	1988-09-02	1998-12-29	Robert Charles Ladner	Generation and selection of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
JP3211963B2 (ja)	1990-08-06	2001-09-25	イーストマンケミカルカンパニー	ポリエステル及びポリスチレンのポリマーブレンド物の製造方法
DK0814159T3 (da)	1990-08-29	2005-10-24	Genpharm Int	Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
ES2113940T3 (es)	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DK0506574T3 (da)	1991-03-29	1996-04-09	Sanofi Sa	Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer
ATE269401T1 (de)	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5596072A (en)	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
JPH09506262A (ja)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	特異的抗体の製造方法
ATE243745T1 (de)	1994-01-31	2003-07-15	Univ Boston	Bibliotheken aus polyklonalen antikörpern
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US7078494B1 (en)	1996-03-01	2006-07-18	Genetics Institute, Llc	Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US6664227B1 (en)	1996-03-01	2003-12-16	Genetics Institute, Llc	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
US6584343B1 (en) *	2000-03-15	2003-06-24	Resolution Medical, Inc.	Multi-electrode panel system for sensing electrical activity of the heart
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20040234499A1 (en)	2001-10-26	2004-11-25	David Shealy	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003213963A1 (en)	2002-04-08	2003-10-27	The John P. Robarts Research Institute	Method of treating or preventing autoimmune disease
US20050271660A1 (en) *	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
AU2003270330B2 (en) *	2002-09-06	2009-07-30	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component C5
US7993864B2 (en)	2002-12-03	2011-08-09	Ucb Pharma S.A.	Assay for identifying antibody producing cells
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
PL1644412T5 (pl)	2003-07-01	2019-01-31	Ucb Biopharma Sprl	Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0407315D0 (en) *	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
ES2385038T3 (es)	2003-12-23	2012-07-17	Genentech, Inc.	Nuevos anticuerpos Anti-IL 13 y usos de los mismos
PT1713503E (pt) *	2004-02-10	2013-11-14	Nat Jewish Health	Inibição do factor b, a via alternativa do complemento e métodos relacionados
EP1713441A2 (en)	2004-02-12	2006-10-25	Nektar Therapeutics	Interleukin-13 antagonist powders, spray-dried particles, and methods
EP1720573A4 (en)	2004-02-27	2008-04-02	Centocor Inc	METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US20070048785A1 (en)	2004-06-09	2007-03-01	Lin Laura L	Anti-IL-13 antibodies and complexes
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
JP2008520684A (ja) *	2004-11-17	2008-06-19	アブジェニックス・インコーポレーテッド	Ｉｌ−１３に対する完全ヒトモノクローナル抗体
EP1669394A1 (en)	2004-12-10	2006-06-14	The Procter & Gamble Company	Superabsorbent polymer particles with improved surface cross-linking and hydrophilicity and method of making them
US20080044420A1 (en)	2005-05-11	2008-02-21	Heavner George A	Anti-IL-13 antibodies, compositions, methods and uses
GB0513852D0 (en)	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
WO2007036745A2 (en)	2005-09-30	2007-04-05	Medimmune Limited	Interleukin-13 antibody composition
EP2532678A1 (en)	2005-10-21	2012-12-12	Novartis AG	Human antibodies against il13 and therapeutic uses
JP2009525267A (ja)	2006-01-11	2009-07-09	アエロヴァンスインコーポレイティッド	ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
GB0600488D0 (en)	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
IL226291A (en)	2006-09-08	2016-05-31	Abbvie Bahamas Ltd	A binding protein that links interleukin-13, its pharmaceutical composition and its use in the preparation of a drug.
CA2672215A1 (en)	2006-12-11	2008-06-19	Wyeth	Methods and compositions for treating and monitoring treatment of il-13-associated disorders
CL2008000058A1 (es) *	2007-01-09	2008-05-23	Wyeth Corp	Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
WO2008086043A2 (en)	2007-01-10	2008-07-17	Wyeth	Methods and compositions for assessment and treatment of asthma
CN101842387B (zh)	2007-09-26	2014-05-07	Ucb医药有限公司	双特异性抗体融合物
BRPI0819693A2 (pt) *	2007-11-30	2020-08-18	Glaxo Group Limited	Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
KR20110043786A (ko) *	2008-08-20	2011-04-27	센토코 오르토 바이오테크 인코포레이티드	조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도
GB0904214D0 (en) *	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products

2009
- 2009-03-11 GB GBGB0904214.4A patent/GB0904214D0/en not_active Ceased
2010
- 2010-03-09 TW TW099106694A patent/TWI476004B/zh not_active IP Right Cessation
- 2010-03-10 AR ARP100100720A patent/AR075849A1/es active IP Right Grant
- 2010-03-10 CA CA2754539A patent/CA2754539C/en active Active
- 2010-03-10 SI SI201031399A patent/SI2406283T1/sl unknown
- 2010-03-10 PL PL10714046T patent/PL2406283T3/pl unknown
- 2010-03-10 CN CN201080014682.1A patent/CN102388066B/zh active Active
- 2010-03-10 US US12/720,804 patent/US8691233B2/en active Active
- 2010-03-10 HU HUE10714046A patent/HUE031923T2/en unknown
- 2010-03-10 RS RS20170163A patent/RS55734B1/sr unknown
- 2010-03-10 ES ES10714046.9T patent/ES2615978T3/es active Active
- 2010-03-10 MX MX2011009390A patent/MX2011009390A/es active IP Right Grant
- 2010-03-10 PT PT107140469T patent/PT2406283T/pt unknown
- 2010-03-10 DK DK10714046.9T patent/DK2406283T3/en active
- 2010-03-10 KR KR1020117023891A patent/KR101773505B1/ko active Active
- 2010-03-10 HR HRP20170234TT patent/HRP20170234T1/hr unknown
- 2010-03-10 EA EA201101303A patent/EA032222B1/ru not_active IP Right Cessation
- 2010-03-10 EP EP16198084.2A patent/EP3168235A1/en not_active Withdrawn
- 2010-03-10 WO PCT/GB2010/000432 patent/WO2010103274A1/en not_active Ceased
- 2010-03-10 ME MEP-2017-38A patent/ME02607B/me unknown
- 2010-03-10 BR BRPI1009576A patent/BRPI1009576B8/pt not_active IP Right Cessation
- 2010-03-10 AU AU2010222693A patent/AU2010222693B2/en not_active Ceased
- 2010-03-10 LT LTEP10714046.9T patent/LT2406283T/lt unknown
- 2010-03-10 EP EP10714046.9A patent/EP2406283B1/en active Active
- 2010-03-10 JP JP2011553509A patent/JP5836130B2/ja active Active
- 2010-03-11 UY UY0001032489A patent/UY32489A/es not_active Application Discontinuation
2011
- 2011-09-07 IL IL215014A patent/IL215014A/en active IP Right Grant
2014
- 2014-02-21 US US14/186,074 patent/US9394361B2/en active Active
2015
- 2015-07-31 JP JP2015151879A patent/JP2016025856A/ja active Pending
2016
- 2016-06-13 US US15/180,916 patent/US9957320B2/en active Active
2017
- 2017-02-16 CY CY20171100215T patent/CY1118640T1/el unknown

Also Published As

Publication number	Publication date
US9957320B2 (en)	2018-05-01
CA2754539A1 (en)	2010-09-16
EP2406283A1 (en)	2012-01-18
SI2406283T1 (sl)	2017-03-31
EP3168235A1 (en)	2017-05-17
IL215014A (en)	2016-07-31
PT2406283T (pt)	2017-02-21
RS55734B1 (sr)	2017-07-31
UY32489A (es)	2010-10-29
US8691233B2 (en)	2014-04-08
TW201036636A (en)	2010-10-16
HUE031923T2 (en)	2017-08-28
AR075849A1 (es)	2011-05-04
AU2010222693A1 (en)	2011-09-29
ES2615978T3 (es)	2017-06-09
CY1118640T1 (el)	2017-07-12
TWI476004B (zh)	2015-03-11
GB0904214D0 (en)	2009-04-22
CN102388066A (zh)	2012-03-21
CN102388066B (zh)	2015-04-01
DK2406283T3 (en)	2017-02-27
EA201101303A1 (ru)	2012-05-30
JP2012520067A (ja)	2012-09-06
IL215014A0 (en)	2011-11-30
EP2406283B1 (en)	2016-11-16
PL2406283T3 (pl)	2017-05-31
JP2016025856A (ja)	2016-02-12
AU2010222693B2 (en)	2014-12-04
CA2754539C (en)	2017-09-12
BRPI1009576B1 (pt)	2020-04-07
MX2011009390A (es)	2011-10-11
BRPI1009576B8 (pt)	2021-05-25
EA032222B1 (ru)	2019-04-30
KR20110128922A (ko)	2011-11-30
WO2010103274A1 (en)	2010-09-16
US20140178387A1 (en)	2014-06-26
LT2406283T (lt)	2017-02-27
US20160289323A1 (en)	2016-10-06
KR101773505B1 (ko)	2017-08-31
JP5836130B2 (ja)	2015-12-24
US9394361B2 (en)	2016-07-19
ME02607B (me)	2017-06-20
HRP20170234T1 (hr)	2017-04-07
US20100260773A1 (en)	2010-10-14

Publication	Publication Date	Title
BRPI1009576A2 (pt)	2016-03-08	anticorpo, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, uso de um anticorpo, e, método para o tratamento de um paciente.
BRPI0717768A2 (pt)	2013-11-05	Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BR112012004823A8 (pt)	2017-10-03	Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112014026990A2 (pt)	2017-07-11	anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI1008692B8 (pt)	2021-05-25	anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BR112012002603A2 (pt)	2016-11-22	composição imunogênica, proteína de fusão, polinucleotídeo, vacina, processo para preparar a vacina, uso da composição imunogênica, e, método para tratar ou prevenir doença estafilocócica.
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BRPI0918555A2 (pt)	2016-05-03	anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012015255A2 (pt)	2017-01-10	"anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
BRPI0807269A2 (pt)	2014-04-29	"anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos"
CL2014001293A1 (es)	2014-12-05	Anticuerpo monocional o fragmento enlazante a antigeno del mismo, especifico para proteinas de citomegalovirus humano (hcmv); molecula de acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para el tratamiento de infeccion por hcmv (div sol 84-2011)
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI0619595B8 (pt)	2022-12-13	anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
BR112014000627A2 (pt)	2018-04-17	polipepitídeo da polimerase mitante, proteína de fusão, moécula de ácido nucleico, vetor, processo de produção do vetor, célula hospedeira, método, composição, uso e kit
BR112017009728A2 (pt)	2018-02-06	anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
AR090903A1 (es)	2014-12-17	Anticuerpos e inmunoconjugados anti-pmel17
WO2013059524A3 (en)	2013-06-13	Antibodies directed against influenza
BRPI0819688A2 (pt)	2015-06-16	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0822099A2 (pt)	2017-05-23	membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-25	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-02-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-04-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2026-01-06	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.